Atlas Trials

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Clinical trial NCT03220217 · COMPLETED

Trial details

NCT number
NCT03220217
Sponsor
Ipsen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastro-Enteropancreatic Neuroendocrine Tumor
Start date
2017-09-26
Primary completion
2019-07-25
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.